Aktis Oncology Reports Q2 2026 Quarterly Results

What Happened

• Aktis Oncology, Inc. (AKTS) filed a Current Report on Form 8‑K on August 13, 2026 (Item 2.02) to announce its financial results and business highlights for the quarter ended June 30, 2026.
• The company furnished a press release as Exhibit 99.1 to the 8‑K; the filing was signed by Chief Financial Officer Kyle Kuvalanka.

Key Details

• Filing date: August 13, 2026.
• Period covered: quarter ended June 30, 2026 (commonly Q2 2026).
• Press release describing quarterly results and business highlights is furnished as Exhibit 99.1.
• Form 8‑K was executed and certified by CFO Kyle Kuvalanka.

Why It Matters

• This filing signals that Aktis has publicly released its quarterly results and business update; the press release likely contains the specific earnings, revenue, cash position, and any operational milestones investors care about.
• The 8‑K itself does not include the numerical results in its text—investors should review the furnished press release (Exhibit 99.1) or the company’s investor relations materials for the detailed financial metrics and any forward-looking commentary.
• Timely disclosure under Item 2.02 ensures investors have access to the company’s quarterly performance; no executive changes or merger activity were reported in this filing.